Investments Gilde Healthcare I
| Company | Description | Contact details |
|---|---|---|
 |
Ablynx is a biopharmaceutical company engaged in the discovery and development of Nanobodies® to treat a range of serious human diseases. More… | Listed on Euronext Brussels in 2007 www.ablynx.com |
 |
Agendia has developed a series of validated diagnostic tests based on genomic profiling that help oncologists make the right decision regarding treatment of the individual cancer patients. More… |
Agendia B.V. Slotervaart Medical Centre, 9D Louwesweg 6 1066 EC AMSTERDAM, The Netherlands Phone: +31 20 512 9161 Fax: +31 20 512 9162 www.agendia.nl |
 |
BioProtein Technologies is a Contract Manufacturing Organization (CMO). The Company provides service from gene expression to industrial production of proteins and vaccines in milk of transgenic rabbits. More… | BioProtein Technologies Domaine de Vilvert, Bâtiment 220 78350 Jouy-en-Josas France Phone: +33 (0)1 39 24 80 80 Fax:+33 (0)1 39 24 80 89 www.bioprotein.com |
 |
BG Medicine focuses on the discovery, development and commercialization of novel molecular diagnostics based on biomarkers. More… | BG Medicine, Inc. 610 Lincoln Street North Waltham, MA 02451 United States Tel: 781-890-1199 Fax: 781-895-1119 www.bg-medicine.com |
 |
Chroma Therapeutics is focused on harnessing the power of chromatin biology and novel drug accumulation approaches to discover and develop a new generation of targeted cancer and inflammation treatments. More… | Chroma Therapeutics Ltd 93 Milton Park Abingdon Oxon OX14 4RY United Kingdom Phone: +44 (0)1235 829120 Fax: +44 (0)1235 829125 www.chromatherapeutics.com |
 |
CropDesign is an agricultural biotech company which has developed a platform and a portfolio of traits to enhance yield and drought resistance in major field crops. More… | Acquired by BASF Plant Science in 2006 www.cropdesign.com |
 |
GlycArt has developed glycoengineering technology (GlycoMAb®) to boost a natural mechanism of action of therapeutic antibodies developed to mediate target cell killing. More… | Acquired by Roche in 2005 www.glycart.com |
 |
IDEA has developed the first safe and effective targeted NSAID, as a replacement for oral NSAIDs, Cox2 inhibitors and opiods for the treatment of osteoarthritis. More… | IDEA AG Frankfurter Ring 193a 80807 München P.O. Box 40 09 21 D-80709 Munich Germany Phone: +49 89 324633 0 Fax:+ 49 89 3241684 www.idea-ag.de |
 |
Innate Pharma develops drugs targeting the innate immune system. More… | Listed on Euronext Paris in 2006 www.innate-pharma.com |
 |
Inpharmatica specialises in the use of predictive informatics in medicinal chemistry and ADME to improve the speed and productivity of drug discovery. More… | Acquired by Galapagos in 2006 www.glpg.com |
 |
Neuro3d develops drugs against psychiatric disorders such as schizophrenia and depression. More… | Acquired by Evotec in 2007 www.evotec.com |
 |
Pieris is a biopharmaceutical company engaged in the discovery and development of Anticalins® to treat a range of serious human diseases. Anticalins® represent a novel class of engineered receptor proteins with therapeutic features. More… | Pieris AG Lise-Meitner-Straße 30 85354 Freising-Weihenstephan Germany Phone: +49 (0) 8161 14 11 400 Fax: +49 (0) 8161 14 11 444 www.pieris-ag.de |